课题基金 / 基金详情

A development of oligonucleotide based DNA array for CYP2C9 genotyping for individual therapy in patients with valve replacement receiving warfarin therapy

A development of oligonucleotide based DNA array for CYP2C9 genotyping for individual therapy in patients with valve replacement receiving warfarin therapy
开发基于寡核苷酸的 DNA 阵列,用于 CYP2C9 基因分型,用于接受华法林治疗的瓣膜置换术患者的个体化治疗
批准号:
15590768
负责人:
NAKAI Kenji
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

NAKAI Kenji的其他基金

相似基金

相关文献

中文摘要
翻译
基于寡核苷酸的基因芯片在华法林治疗患者中的临床应用研究摘要:本研究的目的是验证CYP2C9基因单核苷酸多态(SNPs)在华法林治疗患者中的作用,以避免血栓和出血等副作用。研究对象为26例瓣膜置换术患者,其中主动脉瓣19例,二尖瓣4例,主动脉瓣和二尖瓣3例,均接受华法林治疗。用最新开发的寡核苷酸序列分析系统对CYP2C9基因SNPs进行基因分型。国际标准化比值(PT-1NR)在自动分析系统上测量,ISI值为1.15。通过直接测序验证了寡核苷酸序列分析方法对CYP2C9[CYP2C9^*2突变体;C416T(Argl44Cys),CYP2C9^*3突变体;ALO61C(Ile359Leu)]基因分型的准确性。然而,在这26名患者中没有发现任何突变的基因类型。野生型…患者的PT-FNR值AVR组(n=19)1.6±0.2,MVR组(N4)2±0.5,AVR+MVR组(n=3)2.2±0.4。平均华法林剂量分别为2.8±0.8 mg、3±0.7 mg和2.7±1.3 mg。综上所述,寡核苷酸序列可用于可靠的CYP2C9基因分型,并有可能在临床上用于华法林治疗前检测易感个体。标题II.日本和以色列人群中CYP2C9^*2(Ari‘144Cys)和CYP2C9^*3(Lle3S9Leu)2基因的种族差异。摘要:CYP2C9参与了许多临床重要底物药物的代谢。本研究利用新开发的基于寡核苷酸的DNA阵列(OrigoArray^R),研究了日本和以色列人群中CYP2C9^*2和CYP2C9^*3等位基因分布的种族差异。研究对象包括147名日本人和388名以色列捐赠者(100名德系犹太人、99名也门犹太人、100名摩洛哥犹太人和89名利比亚犹太人)。[Argl44Cys(416C>T)外显子3]和CYP2C9^*3(Ile359Leu(1061A>C),外显子7)基因频率在日本人(1/0)(OR0.02)和利比亚犹太人(0.697/0.303)(OR2.13;;与德系犹太人(0.83/0.17)、也门犹太人(0.899/0.101)、摩洛哥犹太人(0.81/0.19)进行比较。日本人(0.986/0.014)、利比亚犹太人(0.652/0.349)、摩洛哥犹太人(0.77/0.23)、也门犹太人(0.899/0.101)的等位基因频率(AA/AC±CC)明显低于日本人(OR3.03;95%CI1.5~6.1)和摩洛哥犹太人(0.77/0.23)。因此,CYP2C9^*2(Argl44Cys)和CYP2C9^*3(Ile359Leu)突变在日本人群中是罕见的,并且在所研究的四个犹太民族中表现出不同的频率。较少
英文摘要
Title I. The clinical use of oli0onucleotide based DNA array for CYP2C9^*3 and CYP2C9^*2 L'enotvPin2 in patients receiving warfarin therapyAbstract : The aim of this investigation was to verify the contribution of CYP2C9 single nucleotide polymorphisms (SNPs) in patients receiving warfarin to avoid side effects such as embolic and hemorrhagic events. The subjects consisted of 26 patients with valve replacements (19 aortic valve, 4 mitral valve, 3 aortic and mitral valve), who were receiving warfarin therapy. Genotyping of CYP2C9 gene SNPs was determined using a recently developed OligoARRAY system. The international normalized ratio (PT-1NR) was measured on an auto-analyzer system using ISI value of 1.15. The accuracy of genotyping CYP2C9 [CYP2C9^*2 mutant; C416T (Argl44Cys), CYP2C9^*3 mutant; ALO61C (Ile359Leu)] by the OligoARRAY was verified by direct sequencing. However, no mutant genotypes were found in any of these 26 patients. The PT-FNR values for patients with the wild genotype … More was 1.6 ±0.2 in the AVR group (n='19), 2±0.5 in the MVR group (n4), and 2.2±0.4 in the AVR&MVR group (n=3). The average warfarin dose was 2.8 ± 0.8 mg, 3 ± 0.7 mg, and 2.7±1.3 mg, respectively for these group. In conclusion, the OligoARRAY was found to be convenient for the reliable genotyping of CYP2C9, and has the potential for routine use in the clinic for detecting susceptible individuals prior to warfarin treatment.Title II. Ethnic differences in CYP2C9^*2 (Ari'l44Cys) and CYP2C9^*3 (lle3S9Leu) 2enotvpes in Japanese and Israeli populationsAbstract : CYP2C9 contributes to the metabolism of a number of clinically important substrate drugs such as warfarin. In the present study, ethnic differences in the CYP2C9^*2 and CYP2C9^*3 allele distribution in Japanese and Israeli populations were evaluated a using newly developed oligonucleotide based DNA array (OligoArray^R). The population studied consisted of 147 Japanese and 388 Israeli donors (100 Ashkenazi Jews, 99 Yemenite Jews, 100 Moroccan Jews and 89 Libyan Jews). The CYP2C9^*2 [Argl44Cys (416 C>T), exon 3] and CYP2C9^*3 (Ile359Leu (1061 A>C), exon 7) genotypes were determined using an OligoArray^R. The frequencies of CYP2C9^*2 genotype (CC/CT+TT) was significantly lower in Japanese (1/0)(OR 0.02), and was higher in Libyan Jews (0.697/0.303) (OR 2.13; 95%CI 1.07-4.24) compared with those in Ashkenazi Jews (0.83/0.17), Yemenite Jews (0.899/0.101), Moroccan Jews (0.81/0.19). The frequencies of CYP2C9^*3 genotype (AA/AC±CC) was significantly lower in Japanese (0.986/0.014)(OR 0.08), and was higher in Libyan Jews (0.652/0.349) (OR 3.03; 95%CI 1.5-6.1) and Moroccan Jews (0.77/0.23)(OR 1.69; 95%CI 0.62-3.48) compaered with those in Ashkenazi Jews (0.83/0.17), Yemenite Jews (0.899/0.101). Thus, the CYP2C9^*2 (Argl44Cys) and CYP2C9^*3 (Ile359Leu) mutant were rare in the Japanese population, and showed different frequencies in the four Jewish ethnic groups examined. Less
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
Clinical Significance Of CYP2C9 Gene Polymorphisms By Rapid Cycle Real-Time PCR In Patients Receiving Warfarin Therapy.
通过快速循环实时 PCR 检测 CYP2C9 基因多态性在接受华法林治疗的患者中的临床意义。
DOI: --
发表时间: 2004
期刊: Jpn Circ 68
影响因子: --
作者: [Nakai; K, Izumoto H, Oshima Y, Tsuboi J, Kawazoe K.]
通讯作者: Kawazoe K.
Ethnic Difference of Coronary Artery Disease-associated SNPs in Two Israeli Healthy Populations Using MALDI-TOF Mass Spectrometry.
使用 MALDI-TOF 质谱分析两个以色列健康人群中冠状动脉疾病相关 SNP 的种族差异。
DOI: --
发表时间: 2004
期刊: Life Sciences 75
影响因子: --
作者: [Nakai K, Habano W, Nakai K, Fukushima N, Fujita T, Gurwitz D]
通讯作者: Gurwitz D
Nakai K, Habano W, Nakai K, Fukushima N, Fujita T, Gurwitz D: "Ethnic Difference of Coronary Artery Disease-associated SNPs in Two Israeli Healthy Populations Using MALDI-TOF Mass Spectrometry"Life Sciences. (In print). (2004)
Nakai K、Habano W、Nakai K、Fukushima N、Fujita T、Gurwitz D:“使用 MALDI-TOF 质谱法研究两个以色列健康人群中冠状动脉疾病相关 SNP 的种族差异”生命科学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Clinical Significance Of CYP2C9 Gene Polymorphisms By Rapid Cycle Real-Time PCR In Patients Receiving Warfarin Therapy
快速循环实时 PCR 检测接受华法林治疗患者的 CYP2C9 基因多态性的临床意义
DOI: --
发表时间: 2004
期刊: 日本循環器学会誌 68
影响因子: --
作者: [Nakai K, Izumoto H, Oshima Y, Tsuboi J, Kawazoe K]
通讯作者: Kawazoe K
9
    Development of software system for next-generation multi-channel high amplification and high resolution ECG and clinical application
    • 批准号:
      22590792
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.66万
    • 财政年份:
      2010
    • 负责人:
      NAKAI Kenji
    • 依托单位:
    Determination of Impact Indentation Hardness for Metallic Materials and Impact Fracture Toughness for Brittle Materials
    • 批准号:
      21760563
    • 项目类别:
      Grant-in-Aid for Young Scientists (B)
    • 资助金额:
      $2.75万
    • 财政年份:
      2009
    • 负责人:
      NAKAI Kenji
    • 依托单位:
    Early screening of myocardial injury and lethal arrhythmia by 64-channel magnetocardiography and genetical predisposition
    • 批准号:
      18500383
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.59万
    • 财政年份:
      2006
    • 负责人:
      NAKAI Kenji
    • 依托单位:
    Evaluation of genetical factor in the Japanese is chemic heart disease
    • 批准号:
      09670743
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.92万
    • 财政年份:
      1997
    • 负责人:
      NAKAI Kenji
    • 依托单位:
    海外基金